HLTH Europe 2026: obesity drugs shift the paradigm, but systemic implementation lags - Pharmaceutical Technology

Obesity drugs are improving patient lives across Europe, but challenges at the patient, healthcare and societal levels need to be overcome. Obesity drugs are already improving patient lives across Europe, but challenges at the patient, healthcare and societal levels need to be overcome. At HLTH 2026, obesity medications were on the agenda, as European access lags. Credit: Visual Generation / Shutterstock.com. With more than one billion people globally suffering from obesity, pharmaceutical approaches to treatment, such as glucagon-like peptide 1 receptor agonists (GLP-1RAs), hold the potential to revolutionise the care of the chronic condition, while improving patient outcomes. As obesity…

Source: Pharmaceutical Technology